Cardioprotection Resulting from Glucagon-Like Peptide-1 Administration Involves Shifting Metabolic Substrate Utilization to Increase Energy Efficiency in the Rat Heart

AMPK activation by glucagon-like peptide-1 prevents NADPH oxidase activation induced by hyperglycemia in adult cardiomyocytes

(2014) Magali Balteau et al.   AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY

Novel fusion of GLP-1 with a domain antibody to serum albumin prolongs protection against myocardial ischemia/reperfusion injury in the rat

(2013) Weike Bao et al.   Cardiovascular Diabetology

Glucagon-like peptide-1 reduces contractile function and fails to boost glucose utilization in normal hearts in the presence of fatty acids

(2013) T. Dung Nguyen et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

GLP-1 and cardioprotection: from bench to bedside

(2012) S. Ravassa et al.   CARDIOVASCULAR RESEARCH

Albiglutide, a Long Lasting Glucagon-Like Peptide-1 Analog, Protects the Rat Heart against Ischemia/Reperfusion Injury: Evidence for Improving Cardiac Metabolic Efficiency

(2011) Weike Bao et al.   PLoS One

Glucagon-Like Peptide-1 Increases Myocardial Glucose Uptake via p38α MAP Kinase–Mediated, Nitric Oxide–Dependent Mechanisms in Conscious Dogs With Dilated Cardiomyopathy

(2010) Siva Bhashyam et al.   Circulation-Heart Failure

Mitochondrial reserve capacity in endothelial cells: The impact of nitric oxide and reactive oxygen species

(2010) Brian P. Dranka et al.   FREE RADICAL BIOLOGY AND MEDICINE

Emerging cardiovascular actions of the incretin hormone glucagon-like peptide-1: potential therapeutic benefits beyond glycaemic control?

(2009) David J Grieve et al.   BRITISH JOURNAL OF PHARMACOLOGY

Letter by Nguyen and Doenst Regarding Article “Chronic Glucagon-like Peptide-1 Infusion Sustains Left Ventricular Systolic Function and Prolongs Survival in the Spontaneously Hypertensive, Heart-Failure Prone Rat”

(2009) Tien Dung Nguyen et al.   Circulation-Heart Failure

GLP-1R Agonist Liraglutide Activates Cytoprotective Pathways and Improves Outcomes After Experimental Myocardial Infarction in Mice

(2009) M. H. Noyan-Ashraf et al.   DIABETES

Insulin-like actions of glucagon-like peptide-1: a dual receptor hypothesis

(2009) Eva Tomas et al.   TRENDS IN ENDOCRINOLOGY AND METABOLISM

Cardioprotective and Vasodilatory Actions of Glucagon-Like Peptide 1 Receptor Are Mediated Through Both Glucagon-Like Peptide 1 Receptor–Dependent and –Independent Pathways

(2008) Kiwon Ban et al.   CIRCULATION

GLP-1 Therapy

(2008) Derek J. Hausenloy et al.   Circulation-Heart Failure

Chronic Glucagon-Like Peptide-1 Infusion Sustains Left Ventricular Systolic Function and Prolongs Survival in the Spontaneously Hypertensive, Heart Failure–Prone Rat

(2008) Indu Poornima et al.   Circulation-Heart Failure

Advances in measuring cellular bioenergetics using extracellular flux

(2008) David A. Ferrick et al.   DRUG DISCOVERY TODAY

In Vivo Activation of Peroxisome Proliferator-Activated Receptor-  Protects the Heart from Ischemia/Reperfusion Injury in Zucker Fatty Rats

(2008) T.-L. Yue et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Systemic Activation of the Transient Receptor Potential Vanilloid Subtype 4 Channel Causes Endothelial Failure and Circulatory Collapse: Part 2

(2008) R. N. Willette et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS